Obesity drugs: the biggest pharmaceutical market ever built, and what decides it

GLP-1 receptor agonists mimic a gut hormone released after eating. The original commercial purpose was glycaemic control in type 2 diabetes; the weight effect was a side effect that turned out to be worth more than the indication. That history explains the confusing brand structure, where the same molecule is sold under one name for diabetes and another for obesity, at different prices, with different coverage - semaglutide as Ozempic and Wegovy, tirzepatide as Mounjaro and Zepbound.

The molecules are not interchangeable and the differences are commercially decisive. Semaglutide targets one receptor. Tirzepatide targets two, which is most of why it produces more weight loss and most of why Lilly leads. The next generation targets three: retatrutide adds a glucagon receptor and produced up to 20.8 per cent weight loss at eighty weeks in its Phase 3 diabetes trial and 22.6 per cent in adults with severe obesity and established cardiovascular disease.

The newest split is not receptor count but route. Injectables defined the first phase of the market; an oral GLP-1 changes the addressable population, because a substantial share of patients who will not inject will swallow. Novo's Wegovy pill arrived first, and Lilly's Foundayo was approved on 1 April 2026 - the event that turned a two-product race into a four-product one.

Demand for these drugs has never been the constraint. From the first launch the binding limits were manufacturing capacity and reimbursement, and of the two only the second still binds. A drug that is approved and not covered reaches the population that can pay cash; a drug that is covered reaches everybody who qualifies. That single distinction moves revenue by an order of magnitude and it is decided by employers, insurers and government programmes rather than by regulators.

The 2026 dynamic is a deliberate trade of price for volume. Prices have come down, senior access through the government programme has opened, and the oral products have arrived - three forces that all push the same way, toward a much larger treated population at a much lower price per patient. Whether that is good for the manufacturers depends entirely on the elasticity, and that is genuinely uncertain rather than rhetorically uncertain.

The revenue at stake makes the arithmetic unusual. Zepbound alone booked 22.9 billion dollars in 2025 after growing 188.7 per cent; Wegovy booked 18.6 billion. The 2026 brand forecasts run to 25.8 billion for Mounjaro, 19.7 for Zepbound, 19.5 for Ozempic and 15.3 for Wegovy. A coverage decision that shifts a few percentage points of that is a larger event than most approvals in this library.

Quarterly results are the ground truth and they are unusually informative here, because both companies break out the obesity brands separately. That gives a clean read on unit growth against price, which is exactly the split that matters when a market is trading volume for price. The releases land on a schedule known a year in advance, which makes them the most reliable scheduled catalyst in the sector.

Prescription data arrives faster and is where the quarter is decided before it is reported. Weekly script trackers - compiled from pharmacy data by third parties rather than published by the companies - show the share shift between brands and between injection and pill in near real time. That is where the observation that Novo's Wegovy pill has struggled to pass a third of its own franchise's prescriptions comes from, and it is public.

Regulatory dates come from the sponsors, as they do across this domain. Lilly has said it plans to submit its retatrutide application in the first quarter of 2027; with a sixty-day filing period and a ten-month standard review goal, that disclosure alone bounds every contract asking about a retatrutide approval date, without requiring any view on the trial data.